Gain Therapeutics reported a net loss of $13.4 million for the nine months ended September 30, 2026, with cash and cash equivalents decreasing to $11.7 million from $20.8 million at year-end 2025. The company highlighted its ongoing reliance on additional financing to support its Magellan™ platform and clinical development programs.
Gain Therapeutics reported financial results for the third quarter of 2026, highlighted by long-term Phase 1b data for rexaceract showing no motor symptom progression in Parkinson’s disease patients over 12 months. The company plans to initiate a Phase 2 clinical trial for rexaceract in Q1 2027 and select an initial therapeutic indication for its second candidate, GT-04686, by the end of 2026.
Term
Q3 2026
“The third quarter marked an important period of progress for Gain, highlighted by the presentation of long-term open-label data from the Phase 1b trial of rexaceract in Parkinson’s disease (PD). After 12 months of dosing with rexaceract, participants enrolled in the study showed no progression of Parkinson’s disease motor symptoms.”
Gene Mack, President and CEO of Gain Therapeutics
“As we approach the start of the Phase 2 clinical trial of rexaceract, which we expect to initiate during Q1 2027 after confirming updates to our trial design during Q4 2026, we plan to select an initial therapeutic indication to advance GT-04686 into the clinic.”
Gain Therapeutics appointed Jeanette Weidner as Vice President, Finance, and principal financial and accounting officer, effective October 28, 2026. Her compensation package includes an annual base salary of $275,000, a target annual cash bonus of 35%, and an option to purchase 130,000 shares of common stock vesting over four years.
Gain Therapeutics presented 12-month open-label extension data from its Phase 1b study of rexaceract, showing stabilization of MDS-UPDRS motor scores in Parkinson’s disease patients. The data suggests disease-modifying potential as patients showed no clinically meaningful progression of motor symptoms over the one-year period. The company plans to submit a Phase 2 protocol to the FDA and initiate a Phase 2 trial in Q1 2027.
Gianluca Fuggetta resigned as Senior Vice President of Finance, principal financial officer, and principal accounting officer effective September 30, 2026. Gene Mack, the company's current President and CEO, has been appointed to serve as interim Chief Financial Officer effective October 1, 2026, while the company searches for a permanent replacement.